Lavonas, Eric J;
Akpunonu, Peter D;
Arens, Ann M;
Babu, Kavita M;
Cao, Dazhe;
Hoffman, Robert S;
Hoyte, Christopher O;
Mazer-Amirshahi, Maryann E;
Stolbach, Andrew;
St-Onge, Maude;
Thompson, Trevonne M;
Wang, George Sam;
Hoover, Amber V;
Drennan, Ian R.
In this focused update, the American Heart Association provides updated guidance for resuscitation of patients with cardiac arrest, respiratory arrest, and refractory shock due to poisoning. Based on structured evidence reviews, guidelines are provided for the treatment of critical ...
Ra, Jin H;
Rattan, Rishi;
Patel, Nimitt J;
Bhattacharya, Bishwajit;
Butts, Christopher A;
Gupta, Shailvi;
Asfaw, Sofya H;
Como, John J;
Sahr, Sheryl M;
Bugaev, Nikolay.
Recent studies have evaluated outcomes associated with duration of antimicrobial treatment for complicated intra-abdominal infections (cIAI). The goal of this guideline was to help clinicians better define appropriate antimicrobial duration in patients who have undergone definitive source control for cIA...
On June 22, 2023, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended use of 20-valent pneumococcal conjugate vaccine (PCV20 [Prevnar 20, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.]) as an option to 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sh...
On June 22, 2023, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended use of 20-valent pneumococcal conjugate vaccine (PCV20 [Prevnar 20, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.]) as an option to 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sh...
On October 19, 2022, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended the use of either a dose of 20-valent pneumococcal conjugate vaccine (PCV20) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) as previously recommended for adults who have received 13-valent pneumococca...
On October 19, 2022, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended the use of either a dose of 20-valent pneumococcal conjugate vaccine (PCV20) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) as previously recommended for adults who have received 13-valent pneumococca...
Kobayashi, Miwako;
Pilishvili, Tamara;
Farrar, Jennifer L;
Leidner, Andrew J;
Gierke, Ryan;
Prasad, Namrata;
Moro, Pedro;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Long, Sarah S;
Poehling, Katherine A;
Cohen, Adam L.
his report compiles and summarizes all published recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults aged ≥19 years in the United States. This report also includes updated and new clinical guidance for implementation from CDC.
Bef...
A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms of the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract infecti...
A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV))-associated lower respiratory tract infec...
Most of the influenza vaccines currently approved and available in the United States are produced by the propagation of influenza viruses in eggs (1-7). These vaccines therefore can contain small quantities of egg proteins. As of the 2022-23 influenza season, ACIP has recommended annual influenza vacci...
